SCIENTIFIC BACKGROUND

BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

Category:

Scientific Background

Hereditary breast/gynecological guidelines-based panel tests for germline mutations that can cause a collection of different cancers, such as breast cancer and cancers that start in the woman’s reproductive organs such as cervical, ovarian, and uterine. Hereditary breast and specific types of gynecological cancers are considered some of the most common inherited types of cancer. Mutations on the genes tested in this panel have been identified to increase the risk of developing cancer in the future.

 

PreSENTIA hereditary Breast High-Risk cancer panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

 

Who is this test for?

You should get tested if you meet at least one of the criteria below:

You have a personal history of breast/gynecological cancers including ovarian, fallopian tube, and primary peritoneal cancer among others

You have been diagnosed with a breast/gynecological cancer before the age of 50

You have a family history of a breast/gynecological cancer

You belong in specific ancestry groups who are high risk for developing breast/gynecological cancers (e.g Ashkenazi Jewish)

You have a male relative diagnosed with breast cancer

 

How many genes are tested in this panel?

7 genes

 

How many hereditary cancer syndromes are associated with this panel?

5 Hereditary cancer syndromes are associated with this panel. These are:

• Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

• Hereditary diffuse gastric syndrome (CDH1)

• Li-Fraumeni syndrome (TP53)

• Peutz-Jeghers syndrome (STK11)

• PTEN hamartoma syndrome (PTEN)

 

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

PALB2

 

References and more information: 

All the above information was taken from ASCO, Centers for Disease Control and Prevention and NCCN

 

 

GENES

BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53
How to order

LATEST ARTICLES

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more